// App-Quantinova.ai

e11579 : Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.

Researchers

Presenter

  • Young-Hyuck Im

Principal Investigators

  • Keun Seok Lee

  • Ho Yong Park

  • Wichit Arpornwirat

  • Patricia A. Bastick

  • Tuan Anh Le

  • Ozlem Ocak Arikan

  • Hong-Ling Xue

  • Aycin Canatar

  • Roberta Valenti

  • Alper Sevinc

  • Kadri Altundag

  • Yuan-Ching Chang

  • Hikmat Abdel-Razeq

  • Seock-Ah Im

  • Joon Jeong

  • Sung-Bae Kim

  • Rajnish Vasant Nagarkar

  • Joohyuk Sohn

Medical Centers

  • Cho Ray Hospital, Ho Chi Minh City, Vietnam

  • Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey

  • King Hussein Cancer Center, Amman, Jordan

  • Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey

  • Ege University School of Medicine, Izmir, Turkey

  • Novartis AG, Basel, Switzerland

  • Curie Manavata Cancer Center, Nashik, India

  • National Cancer Institute, Bangkok, Thailand

  • Novartis Asia Pacific Pharmaceuticals, Singapore, Singapore

  • Department of Thoracic Surgery, Mackay Memorial Hospital, Taipei City, Taiwan

Locations

  • Taiwan

  • Singapore

  • Vietnam

  • Turkey

  • Switzerland

  • Jordan

  • Thailand

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

  • Hormone receptor

Drug/Treatment

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • single arm

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved